Furthermore, these results are comparable to, if not better than, those of a clinical trial testing the combination of pembrolizumab and VEGFR inhibitor lenvatinib in HCC, as well as those of a clinical trial testing the combination of nivolumab and regorafenib in gastric and gastroesophageal carcinoma. Here, KDR is linked to hepatocellular carcinoma.